Results 201 to 210 of about 422,010 (294)

Hydroxychloroquine Cardiotoxicity Mimicking Transthyretin Cardiac Amyloidosis in a Patient With HFpEF. [PDF]

JACC Case Rep
Asempah M, Kozaily E, Abissi I, Silvis C, Caballero C, Champaneri D, Litwin SE, Belanger MJ.   +7 more
europepmc   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

Nicotinamide Mononucleotide Does Not Prevent Cardiac Hypertrophy but Attenuates Cardiac Stress and Remodeling Markers in Mice Exposed to Intermittent Normobaric Hypoxia. [PDF]

Nutrients
Wang Z, Wang M, Guo J, Wang Y, Wang S, Yuan J, Yang R, Bi Y, Ke Y.   +8 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Anemia and high-output cardiac hypertrophy in Tanzania and Haiti: a cross-sectional analysis. [PDF]

BMC Glob Public Health
Rouzier V, Ruselu G, Willkens M, Yan LD, Cichowitz C, Ogyu A, Garbindi A, Kisigo G, Issarow B, Sufra R, Etyang A, Pape JW, Devereux RB, McNairy M, Kapiga S, Peck R, Lee MH.   +16 more
europepmc   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Unmasking AL Cardiac Amyloidosis During Familial Cardiomyopathy Screening. [PDF]

JACC Case Rep
Barberis Barcia G, Toranzo-Nieto I, González-Calle V, Maillo Seco J, Álvarez Rodríguez L, Cañadas Salazar JC, García Monsalvo M, Muñoz León JA, Agullo Roca C, Eiros Bachiller R.   +9 more
europepmc   +1 more source

Leveraging neural network models for drug repurposing: a case study on cardiac hypertrophy. [PDF]

Sci Rep
Magnusson R, Johansson M, Hagvall S, Synnergren J.   +3 more
europepmc   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source